RQM+™ Acquires Germany Based CRO Kottmann
28.8.2023 13:30:00 EEST | Business Wire | Press release
RQM+, a global leader in MedTech services, announces its acquisition of CRO Kottmann, a premier contract research organization (CRO) renowned for its excellent customer service, scientific clinical research and quality in the key market of Germany. This significant move further supports RQM+’s dedication to strategic growth and presence in Europe and emphasizes its dominance in the growing areas of MedTech.
The integration of CRO Kottmann enhances RQM+’s existing geographical footprint in global operations as well as ensures comprehensive end-to-end support for clients, from pre-clinical phases to product commercialization. The addition of CRO Kottmann further expands RQM+'s rapidly growing business as a leading MedTech CRO, driving both existing and new clients’ innovations into pivotal markets.
“We are tremendously excited about this pivotal acquisition. The synergy between RQM+ and CRO Kottmann will propel us to greater heights in the industry. The German market, well known for its emphasis on science, innovation, and market intelligence, is a vital geography for RQM+,” said RQM+ Chief Operating Officer of Clinical Trial Services, David Novotny. “With the combined expertise of both organizations, we will achieve quicker, more efficient operational deliveries that will facilitate a faster market entry for our clients.”
With a reputation for unparalleled customer service and quality, CRO Kottmann brings a wealth of industry-leading knowledge and acumen, positioning RQM+ to leverage these attributes in expanding its global influence, especially in Europe.
“We have always held a like-minded approach to ensuring best-in-class customer service and advisement. This alignment of core values, coupled with our shared ambition to foster growth in science and innovation, will make this partnership a continuation of the success story in Clinical Research. We are pleased to be able to offer our clients an even greater depth of clinical research services. Going forward, our clients can continue using our services to conduct global studies worldwide,” said Tanja Kottmann MD, CEO of CRO Kottmann.
As RQM+ continues its trajectory of growth, the acquisition of CRO Kottmann underscores its commitment to delivering unparalleled service to MedTech manufacturers of all sizes. The acquisition ensures a potent combination of regulatory and clinical experience, industry-leading capabilities, and unrivaled geographical reach, paving the way for swift and innovative solutions in the MedTech space.
DLA Piper served as legal advisor and Translink Corporate Finance as M&A advisor to RQM+.
About RQM+:
RQM+ is the world's leading MedTech service provider offering consulting, clinical trial, lab, and reimbursement services, as well as technology solutions to support the entire product lifecycle. RQM+’s global team of clinical, technical, and top industry experts push the boundaries of excellence. With more former FDA, Medicines, and Healthcare Products Regulatory Agency (MHRA) and notified body regulators than any other firm, the RQM+ team has deep expertise in all clinical specialties. We reduce commercialization risk by offering a full complement of CRO services to progress medical devices, digital therapeutics and diagnostics onto the market and keep them there. In addition to early- and mid-stage MedTech companies, we currently work with 19 of the top 20 medical device manufacturers and seven of the top 10 IVD companies. For more information, visit RQMplus.com.
About Kottmann:
CRO Dr. med. Kottmann, based in Germany, is a leading Contract Research Organization (CRO) celebrated for its unmatched customer service and commitment to quality. As an international CRO, Kottmann conducts clinical studies with medical devices, in vitro diagnostics (IVDs) and pharmaceuticals. In addition to full service, Kottmann also offers individual services such as the creation of databases (eCRFs), statistical evaluations and clinical monitoring for your study. For more information, visit https://www.cro-kottmann.de/en/home_gb.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230828710869/en/
Contact information
Media:
Rob Pepper, RQM+
+1.301.254.6100
RPepper@rqmplus.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 18:09:00 EEST | Press release
The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40 years, a coordinated aviation effort organized by Textron Aviation, a Textron Inc. (NYSE: TXT) company, that transports hundreds of Special Olympics athletes and coaches from multiple states
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 17:53:00 EEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom